Back

Novel Therapeutic Agents for Transthyretin Amyloidosis – Represented in NEJM by the ATTR-ACT, APOLLO, and NEURO-TTR trials.

1 September 2019 (11:00 - 11:23)
Organised by:
Congress Presentation Part of: Highlights from the New England Journal of Medicine: editors’ choice European Society of Cardiology ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Claudio Rapezzi

University of Ferrara, Ferrara (Italy)

2 More presentations in this session

Presentation thumbnail
Aspirin for the Primary Prevention of Cardiovascular Disease – Represented in NEJM by the ASPREE and ASCEND trials (and in Lancet by the ARRIVE trial).
Professor J. Mcneil (Melbourne, AU)
Slides Video
Presentation thumbnail
Transcatheter Aortic Valve Replacement in Low-Risk Patients – Represented in NEJM by the PARTNER 3 and Evolut Low Risk trials.
Doctor M. Mack (Dallas, US)
Slides Video

Access the full session

Session thumbnail
Highlights from the New England Journal of Medicine: editors’ choice

The Event

Event poster

ESC Congress 2019

1 September 2019 11:00 CET
You may be interested in
thumbnail
Congress Session
The EHJ’s year in cardiovascular medicine: cardio-oncology, heart failure, and arrhythmias
thumbnail
ESC TV Today
Episode 4: Heart disease in dialysis patients - Substance abuse and heart disease
thumbnail
ESC TV Today
Episode 12: Relevance and management of ventricular ectopic beats - Lp(a) in cardiovascular risk management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources